Invitrogen™ TRAIL R3/ TNFRSF10C Human ELISA Kit

Description

The Human TRAIL R3/TNFRSF10C (TRAIL R3) ELISA quantitates Hu TRAIL R3 in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu TRAIL R3. Principle of the method The Human TRAIL R3 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

TRAIL-R3 (tumor necrosis factor receptor superfamily member 10C) is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain which means it is not capable of inducing apoptosis. TRAIL-R3 may protect cells against TRAIL mediate apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand. TRAIL-R3's gene was found to be a p53-regulated DNA damage-inducible gene. The expression of the gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.